Wet macular degeneration

This study tests a refillable eye implant (Port Delivery System) that slowly releases the drug ranibizumab to treat wet age-related macular degeneration. The implant is refilled every 36 weeks, potentially reducing the need for frequent eye injections. About 250 participants who …

Researchers are testing a new treatment called PAL-222 for people with neovascular age-related macular degeneration (AMD) whose disease has not responded to existing therapies. The study will enroll up to 10 adults aged 18 to 85 with this condition. Each participant will have a s…

This study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…

This phase 3 trial tests whether a new drug called ABP 938 works as well as the approved treatment Eylea HD for wet age-related macular degeneration, a leading cause of vision loss. About 304 people aged 50 and older with untreated wet AMD will receive injections of either drug i…

Researchers are testing a new eye drop called NT-101 in people with wet age-related macular degeneration, a condition where abnormal blood vessels leak fluid into the retina and damage central vision. The trial enrolls 66 adults aged 50 and older who have active leaking vessels u…

This study tests a gene therapy called ABBV-RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can reduce the need for frequent eye injections while keeping vision stable. About 561 adults a…

This phase 3 trial tests whether adding surgery (vitrectomy, clot-busting drug, and gas bubble) to standard anti-VEGF injections can improve vision more than injections alone for people with a macular bleed from wet AMD. About 210 participants across Europe will be randomly assig…

This Phase 2 trial tests an experimental drug called EYE103 (Restoret) in 160 people with wet age-related macular degeneration or macular edema from a branch retinal vein occlusion. Participants receive three eye injections of either a low or high dose of EYE103, spaced four week…

This study is testing a refillable eye implant that delivers the drug ranibizumab to treat wet age-related macular degeneration (AMD). The main goal is to see if the implant affects the cells on the inner surface of the cornea. About 188 people with wet AMD will receive the impla…

This study follows people with wet age-related macular degeneration who received an injection of SKG0106, an experimental gene therapy, in an earlier trial. Researchers will track their eye health, vision, and any side effects for up to 5 years after the injection. The goal is to…

This study is checking the long-term safety of a small implant placed in the eye that slowly releases medicine to treat wet age-related macular degeneration, a condition that can cause rapid vision loss. About 1,000 people who have already used the implant in earlier studies will…

This phase 1/2 trial tests SKG0106, a gene therapy injected into the eye, in people with wet age-related macular degeneration (nAMD). The treatment aims to help the eye produce proteins that block abnormal blood vessel growth, potentially reducing the need for frequent anti-VEGF …

This study tests a gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single injection into the eye can safely reduce the need for regular anti-VEGF shots. About 215 adults aged 50 and old…

This phase II trial is testing whether a single subretinal injection of JWK001, a gene therapy, can safely and effectively treat wet age-related macular degeneration (nAMD). The study includes about 50 adults aged 50-85 with active disease who have responded to prior aflibercept …

This study tests a new drug called tiespectus (MK-8748) against the current standard treatment, aflibercept, for people with wet age-related macular degeneration (AMD). About 960 participants will receive injections into the eye and be followed for a year to see if tiespectus can…

This Phase 3 trial tests a single injection of LX102 gene therapy under the retina for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 332 participants will receive either LX102 or standard aflibercept injections. The goal is to see i…

This study tests a gene therapy called Ixo-vec in the second eye of people with wet age-related macular degeneration (AMD) in both eyes. Fifteen adults aged 50 and older will receive a single injection in the second eye and be followed for about 5 years. The goal is to see if the…

This phase 4 trial will test the drug faricimab (Vabysmo) in 64 people with wet age-related macular degeneration (AMD). Participants will receive eye injections every 4 weeks for 4 doses, then a treat-and-extend schedule based on disease activity. The study also measures biomarke…

This phase 3 study tests a single injection of Ixo-vec gene therapy against standard aflibercept injections in 284 people with wet AMD. The goal is to see if Ixo-vec can maintain or improve vision while reducing the need for repeated eye injections. Participants must be at least …

This Phase 3 trial tests whether adding an SMZ1 tablet to standard ranibizumab eye injections improves vision more than injections alone in people with wet age-related macular degeneration (AMD). Participants receive either SMZ1 or a placebo tablet twice daily for 12 months, alon…

This early-stage trial tests a new medicine called EYC-0305, given as an eye injection every 24 weeks, in 30 people aged 50 and older with wet age-related macular degeneration (AMD). The main goal is to check if the treatment is safe and tolerable. Researchers will also measure h…

This study is checking the long-term safety of an implant called OTX-TKI (axitinib) for people with wet age-related macular degeneration (AMD). The implant is placed in the eye and slowly releases medicine to control the disease. About 850 people who already completed two years o…

This study tests whether injecting a person's own bone marrow stem cells into or near the eye can help treat various retinal and optic nerve diseases, including age-related macular degeneration, retinitis pigmentosa, and glaucoma. Participants receive stem cell injections via dif…

This study looks at switching people with wet age-related macular degeneration (AMD) to a higher dose (8 mg) of the drug aflibercept. The goal is to see if it can extend the time between eye injections while still controlling the disease. Researchers will compare injection interv…

This study looks at 100 people with wet age-related macular degeneration (AMD) who have been getting regular eye injections with older drugs. They will switch to a newer drug called faricimab. The goal is to see if faricimab can extend the time between injections, meaning fewer t…

This observational study will follow 300 people with wet age-related macular degeneration (nAMD) who receive aflibercept 8 mg injections as part of their routine care. Researchers want to see how well the drug improves vision and reduces retinal swelling over 12 months, and what …

This study tests the drug faricimab (Vabysmo) in 100 people aged 50+ with wet age-related macular degeneration who have a specific type of harmful material under their retina. The goal is to see if the drug can clear that material by week 16. Participants receive injections into …

This early-stage trial tests an experimental drug called BBC1501, given as an injection into the eye, for people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability in 18 volunteers aged 50 and older who have already received standa…

This early-phase trial tests a new drug called PRL3-zumab in 15 people with wet age-related macular degeneration (nAMD) who have not improved with standard treatments. The drug is given by IV every two weeks for three doses. The study will check for safety and any signs that visi…

This Phase 3 trial tests a single injection of 4D-150, a gene therapy, in 480 adults with wet age-related macular degeneration (AMD). The goal is to see if one treatment can maintain or improve vision and reduce the need for standard anti-VEGF injections like Eylea. Participants …

This study tests whether an oral medication (doxycycline) can help people with wet age-related macular degeneration (AMD) who still have fluid under their retina despite standard eye injections. About 50 participants will receive either doxycycline or a placebo for several months…

This early study tests a single injection of LX111 gene therapy in 10 people aged 50 or older with wet age-related macular degeneration (nAMD). The goal is to see if it is safe and can help control the disease, possibly reducing the need for frequent eye injections. Participants …

This study looks at how well a higher dose (8mg) of the drug Aflibercept (Eylea) works in the first two months for people with wet age-related macular degeneration, a leading cause of vision loss. Researchers will track fluid changes in the retina and vision improvements in 50 pa…

This study tests a new drug called IBI302, given as an eye injection, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can prevent further vision decline over 52 weeks. About 800 adults aged 50 and older with act…

This study tests whether faricimab (Vabysmo) injections given every 12-16 weeks can maintain stability in people with wet age-related macular degeneration (AMD) after an initial series of loading doses. The trial will enroll 40 adults over 50 with active wet AMD. The main goal is…

This study tests an experimental oral tablet called HX9428 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The trial will enroll 198 adults aged 50–85 to check the drug's safety, how the body processes it, and whether it can improve eye…

This study tests an experimental drug called SCT520FF for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 82 adults aged 45 to 80 will receive either SCT520FF or an existing treatment (EYLEA) via eye injections. Researchers will check safety, sid…

This study is testing a home-based eye-tracking system called AVIGA to see if it can detect when wet age-related macular degeneration (AMD) comes back. Sixty adults aged 50-99 who are being treated for wet AMD will use the AVIGA device at home, and its accuracy will be compared t…

This study aims to find out why 20-40% of people with wet age-related macular degeneration (AMD) don't respond well to standard anti-VEGF injections. Researchers will collect fluid from inside the eye of 117 patients and compare those who respond well to treatment with those who …

This study tests whether immune cells called monocytes from people with the atrophic form of age-related macular degeneration (AMD) survive longer on retinal cells than monocytes from healthy people. Researchers will collect blood samples from 80 participants, extract monocytes, …

This study interviews 30 patients with wet age-related macular degeneration to understand their views on gene therapy. Researchers want to know if the benefits outweigh the risks of this irreversible treatment, and how patients make decisions about complex therapies. The goal is …

This study will analyze health records from 2009 to 2024 to find out how many people in Germany have three serious eye conditions: wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Researchers will look at data from two large German health …

This study looks at three drugs (bevacizumab, ranibizumab, and aflibercept) used to treat age-related macular degeneration (AMD), a leading cause of blindness in older adults. Researchers will analyze costs and quality of life for 600 patients in France to see which treatment off…

This study aims to understand the natural bacteria living on the surface of the eye in both healthy people and those with certain eye conditions. Researchers will collect eye swabs from 500 adults in middle Tennessee to build a database of what a normal eye microbiome looks like.…

This study looks at whether sinusitis (sinus infection) is common in people with wet age-related macular degeneration (AMD) who need many eye injections. Researchers will screen 200 participants for sinusitis and treat it if found. They will then check if sinusitis treatment redu…

This phase 3 trial is testing whether a person's genetic makeup influences how well they respond to two standard drugs for wet age-related macular degeneration: ranibizumab and bevacizumab. About 630 patients will receive one of the two drugs and be followed for three years. The …